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Accepted 2 February 2018Background: T cells have a distinctive role in neovascularization, which consists of arteriogenesis and angiogen-
esis under pathological conditions and vasculogenesis under physiological conditions. However, the role of co-
stimulation in T cell activation in neovascularization has yet to be established. The aim of this studywas to inves-
tigate the role T cell co-stimulation and inhibition in angiogenesis, arteriogenesis and vasculogenesis.
Methods and results: Hind limb ischemia was induced by double ligation of the left femoral artery in mice and
blood flow recovery was measured with Laser Doppler Perfusion Imaging in control, CD70−/−, CD80/86−/−,
CD70/80/86−/− and CTLA4+/− mice. Blood flow recovery was significantly impaired in mice lacking CD70 com-
pared to control mice, but was similar in CD80/86−/−, CTLA4+/− and control mice. Mice lacking CD70 showed
impaired vasculogenesis, since the number of pre-existing collaterals was reduced as observed in the pia
mater compared to control mice. In vitro an impaired capability of vascular smooth muscle cells (VSMC) to
activate T cells was observed in VSMC lacking CD70. Furthermore, CD70−/−, CD80/86−/− and CD70/80/86−/−
mice showed reduced angiogenesis in the soleusmuscle 10 days after ligation. Arteriogenesiswas also decreased
in CD70−/− compared to control mice 10 and 28 days after surgery.
Conclusions: The present study is the first to describe an important role for T cell activation via co-stimulation in
angiogenesis, arteriogenesis and vasculogenesis, where the CD27-CD70 T cell co-stimulation pathway appears to
be themost important co-stimulation pathway in pre-existing collateral formation and post-ischemic blood flow
recovery, by arteriogenesis and angiogenesis.y, Einth
ical Cent








Peripheral arterial disease (PAD) is characterized by the formation of
atherosclerotic plaques in lower extremities and is a major cause of
morbidity and mortality [1,2]. The body can restore the blood flow to
ischemic tissues by initiating neovascularization, which is a similar
mechanism that occurs in patients after myocardial infarction. Neovas-
cularization consists of angiogenesis and arteriogenesis under patholog-
ical conditions, such as PADormyocardial infarction, and vasculogenesis
under physiological conditions. Angiogenesis is the process of sprouting
of new capillaries from pre-existing microvasculature, which is due to
hypoxia and occurs mainly far distal to the occlusion [3]. Arteriogenesis
initiates by inflammation, shear stress and circumferential stretchon theoven Laboratory for
er, PO Box 9600, 2300
an open access article undervascular wall, which causes inactive pre-existing arterioles, formed by
vasculogenesis, to mature into functional collateral arteries, which oc-
curs mainly nearby the occlusion [4–6]. Vasculogenesis is the formation
of new blood vessels during embryogenesis through differentiation of
angioblasts into endothelial cells followed by the recruitment of vascular
smooth muscle cells (VSMC), which can shape new blood vessels [7].
In PAD patients, for collateral artery formation a proper vascular bed
of pre-existing arterioles is essential. These pre-exiting arterioles are
formed by vasculogenesis. Therefore, this is an important process in
PAD. Thematuration of pre-existing collateral arteries by arteriogenesis,
together with the angiogenetic sprouting of new capillaries, can restore
blood flow towards ischemic tissues [8,9].
We and others have shown a specific role of CD4+ T cells in
arteriogenesis by using a hind limb ischemia (HLI) model [10,11].
CD4+ T cells have the capacity to attract macrophages and monocytes
to the site of occlusion, which in turn triggers arteriogenesis through
the release of inflammatory cytokines. Various studies showed increased
release of VEGF by hypoxic cells triggered through inflammatory cyto-
kines, indicating a possible role of CD4+ T cells in angiogenesis as wellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Blood flow recovery after induction of hind limb ischemia. a. Paw perfusion was
measured before and after surgery and 3, 7, 10, 13, 21 and 28 days after surgery. Control
mice (n = 11, light blue), CD80/86−/− mice (n = 11, green), CD70−/− mice (n = 7,
orange), CD70/80/86−/− mice (n= 8, red) and in CTLA-4+/− mice (n= 11, dark blue)
were sacrificed after 28 days. b. Paw perfusion was measured before and after surgery
and 3, 7 and 10 days after surgery. Control mice (n = 9), CD80/86−/− mice (n = 10),
CD70−/− mice (n= 11), CD70/80/86−/− mice (n= 10) and in CTLA-4+/− mice (n= 6)
were sacrificed after 10 days. Paw perfusion is expressed as a ratio of left (ischemic)
to right (non-ischemic) paw perfusion. Data is presented as mean SEM; *p b 0.05;
**p b 0.01.
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and recruit CD4+ mononuclear cells through the expression of IL-16
[14]. Others also suggest a role for CD8+ T cells in angiogenesis [15].
A previous study further showed that T cells play an important role
in vasculogenesis [16]. However, it is still unknown what the acti-
vation mechanism of T cells in vasculogenesis, angiogenesis and
arteriogenesis is.
For T cell activation, different T cell co-stimulation and inhibitory
pathways are described. Co-stimulatory molecules of the B7 family,
such as CD80 and CD86, were the first described and are the most
well-known and studiedmolecules [17]. CD28 is a co-stimulation recep-
tor expressed constitutively on the cell-surface of T cells, which inter-
acts with both CD80/CD86 proteins present on antigen presenting
cells (APC) [18] and promotes T cell activation and proliferation [19].
As a counteracting system, CTLA4 is an inhibitory receptor on T cells,
which down regulates the immune response by binding to CD80/86
with a higher affinity than CD28 [17]. CD27 is a second co-stimulation
receptor located constitutively on the surface of T cells, which interacts
with CD70 proteins on APC to activate T cell [20]. In contrast to their
receptors, co-stimulatory ligands CD80, CD86, and CD70 are transiently
up regulated upon activation. The signalling pathway of CD27 in T cells
is different compared to CD28 and CD27 promotes T cell survival via up
regulation of anti-apoptotic factors [21,22].
The CD28-CD80/86 T cell co-stimulation pathway and CD28-CTLA4
T cell inhibitory pathway were shown to regulate the development
of both native atherosclerosis [23,24] as well as post-interventional ac-
celerated atherosclerosis [25]. But this pathway was also shown to be
involved in other vascular diseases [26], graft arterial disease [27–29]
and inflammatory diseases such as rheumatoid arthritis [30]. The
CD27-CD70 T cell co-stimulation pathway is less investigated, however,
immune activation via the CD27-CD70 T cell co-stimulation pathway
showed to protect against atherosclerosis [31]. In the current study we
aimed to elucidate the role of the CD27-CD70 and CD28-CD80/86 T
cell co-stimulation pathway, and CD28-CTLA4 T cell inhibitory pathway
in post-ischemic neovascularization and vasculogenesis. By visualising
pre-existing collaterals in the pia mater of CD70−/−, CD80/86−/− and
CD70/80/86−/− mice we observed a particular effect of CD27-CD70-
mediated T cell co-stimulation on vasculogenesis. Furthermore, CD27-
CD70-mediated T cell co-stimulation was also important for optimal
blood flow recovery, angiogenesis and arteriogenesis.
2. Materials and methods
Materials and expanded methods are presented in the Online Data Supplement.
3. Results
3.1. Differential impact of co-stimulation pathways on T cell activation in
lymphoid organs and blood
Initially, we determined if co-stimulation has a differential impact in
lymphoid organs and blood, by analysing the T cell activation levels in
blood, bone marrow, lymph node and spleen of control CD80/86−/−,
CD70−/−, CD70/80/86−/− and CTLA4+/− mice. The phenotypical
markers KLRG1+ CD62L− were used to determine the percentage
of activated CD4+ or CD8+ T cells in each compartment. CD4+ and
CD8+ T cell activation in bone marrow, lymph node and spleen of
CD80/86−/− and CD70/80/86−/− mice was significantly decreased. In
CD70−/− mice, CD4+ T cells in the bone marrow and CD8+ T cells in
the lymph nodes and spleen showed significantly decreased T cell acti-
vation compared to control (Figs. S1 and S2), indicating a more impor-
tant role of the CD28-CD80/86 co-stimulation pathway compared to
the CD27-CD70 co-stimulation pathway in lymphoid organs. This was
also demonstrated by a trend towards increased T cell activation in lym-
phoid organs, blood and bone marrow in both CD4+ and CD8+ T cells
of CTLA4+/− mice compared to control mice. However, CD80/86−/−,CD70−/− and CD70/80/86−/−, all showed no difference on T cell activa-
tion in blood. Together, these results demonstrate a differential effect of
co-stimulatory pathways on T cell activation in bone marrow and lym-
phoid organs compared to the blood circulation.
3.2. Impact of CD27-CD70-mediated T cell co-stimulation on post-ischemic
blood flow recovery
The above described results confirm that co-stimulatory pathways
have distinct effects in lymphoid organs and blood, but whether such
differential effects also occur in peripheral (non-lymphoid) tissues
such as blood vessels or the formation thereof remains to be elucidated.
Here we aimed to address the (differential) role of co-stimulation in
neovascularization. First, we studied post-ischemic blood flow recovery
by analysing pawperfusion in control, CD80/86−/−, CD70−/−, CD70/80/
86−/− and CTLA-4+/−mice before ligation of the femoral artery and se-
rially after surgery until sacrifice of the mice after 28 days. Paw perfu-
sion was decreased directly after surgery and control mice showed
74%bloodflow recovery in 28 days after surgerywith a small drop in re-
covery between 7 and 13 days (Fig. 1a). CD80/86−/− and CTLA4+/−
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mice, indicating that the CD28-CD80/86T cell co-stimulation pathway is
not a major co-stimulatory pathway in blood flow recovery. Blood flow
recovery in CD70−/− mice (p = 0.03) and CD70/80/86−/− (p= 0.01)
was significantly impaired 28 days after surgery. We observed a de-
creased blood flow recovery in CD70−/−mice in time with significantly
lower paw perfusion ratios at all time points (except 13 days after
surgery) compared to control mice. In CD70/80/86−/− mice, blood
flow recovery was also impaired in time with lower paw perfusion ra-
tios 3 days (p = 0.006), 7 days (p = 0.002) and 10 days (p = 0.004)
after surgery compared to control mice. With the comparable blood
flow recovery of control mice and CD80/86−/− mice, and the reduced
recovery in CD70−/− mice compared to control mice, we conclude
that the impaired blood flow recovery of CD70/80/86−/− mice is most
likely caused by the lack of CD70 co-stimulation.
Since paw perfusion was rapidly recovering in the first 10 days after
surgery (Fig. 1a), we performed a second paw perfusion experiment
in which the mice were sacrificed 10 days after surgery. Blood flow re-
covery in CD80/86−/− and CTLA-4+/− mice was comparable to control
mice (Fig. 1b). However, CD70−/− mice showed significantly impaired
blood flow recovery after 3 days (p = 0.002), 7 days (p = 0.04) and
10 days (p = 0.01) compared to control mice. CD70/80/86−/− mice
also showed impaired blood flow recovery after 3 days (p = 0.0095),
7 days (p= 0.003) and 10 days (p= 0.002) after surgery compared toFig. 2. Pre-existing collateral density in pial circulation. a. Representative image of pre-existing
86−/− and CD70−/− mice. b. Total number of pre-existing collaterals per mm2 in pial circulat
CD70/80/86−/− mice (n= 5). Data are calculated as mean SEM; *p b 0.05.control mice. This confirms that the CD27-CD70 T cell co-stimulation
pathway has an important role in blood flow recovery.
3.3. Pre-existing collateral formation is affected by CD27-CD70 T cell
co-stimulation
To determine if T cell co-stimulation affects collateral vasculogenesis,
pre-existing collateral density was determined in pial circulation of the
pia mater of CD70−/−, CD80/86−/−, CD70/80/86−/− and control mice.
CD80/86−/−mice showed a similar pre-existing collateral density com-
pared to control mice (Fig. 2a). However, compared to control mice a
decrease in pre-existing collateral density was observed in CD70−/−
(p = 0.04) and CD70/80/86−/− mice (p = 0.04) (Fig. 2b). This de-
creased formation of pre-existing collaterals, indicates an important
role for the CD27-CD70 T cell co-stimulation pathway in vasculogenesis
and collateral development.
3.4. T cell activation via vascular smooth muscle cells is mediated by
CD27-CD70 T cell co-stimulation
VSMC are essential in vascular remodelling andmay also act as APCs
in T cell activation. To determine the role of VSMC co-stimulation
in vitro, we used control, CD80/86−/−, CD70−/− and CD70/80/86−/−
VSMC. We added OT-I T cells (recognizing the MHC class I SIINFEKLcollaterals indicated by white stars (*) in pial circulation in control, CD80/86−/−, CD70/80/
ion is shown in control mice (n= 5), CD80/86−/− mice (n= 7), CD70−/− mice (n= 7),
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tration in the supernatant, as measure of T cell activation, after 24 h.
CD70−/− (p= 0.002) and CD70/80/86−/− (p= 0.001) VSMCs showed
a decreased T cell activation since the IFNy concentration in the super-
natant was significantly lower compared to control VSMCs (Fig. S3).
CD80/86−/− VSMC showed no differences in T cell activation compared
to control VSMC. Indicating that the CD27-CD70 pathway, rather than
the CD28-CD80/86 pathway, might play an important role in T cell acti-
vation via VSMCs.
3.5. Decreased angiogenesis in soleus muscles of CD70−/− mice
To demonstrate the presence of T cells in the proximity of capillaries
in soleus muscles, a double staining was performed for CD31 and CD3
in soleus muscles of mice sacrificed at 28 days after HLI. We here
show the presence of T cells (CD3+ cells) in the soleus muscle around
the capillaries (CD31+ cells), suggesting a contribution of T cells
in angiogenesis (Fig. 3a). Angiogenetic capillary formation was deter-
mined by measuring the number of CD31 positive cells in soleus
muscles (typical example of CD31 IHC staining shown in Fig. 3b).
In mice lacking either CD70 (p = 0.04), CD80/86 (p = 0.02) or both
(p = 0.008), angiogenesis was significantly decreased compared to
control mice 10 days after surgery. CTLA4+/− mice did not show differ-
ences in angiogenesis (Fig. 3c). In CD70−/− mice, angiogenesis was still
impaired after 28 days (p= 0.04) compared to control mice, but CD80/
86−/−, CD70/80/86−/− and CTLA-4+/− mice showed no difference
compared to control mice after 28 days (Fig. 3d). Comparison of
angiogenetic capillary formation after 10 and 28 days showed increased
angiogenesis in CD80/86−/− (p= 0.04), CD70/80/86−/− (p= 0.0005)
and CTLA-4+/− (p = 0.03) mice in time and angiogenesis levels
and showed no longer differences compared to control mice after
28 days, where angiogenesis in CD70−/− mice did not increase in timeFig. 3. Angiogenesis in soleus muscles. a. Representative image of CD31 (green) and CD3 (ma
b. representative image of CD31 staining in soleus muscle of a control mice is shown which w
non-ischemic) ratio of the number of CD31 positive cells in soleus muscles is shown in cont
mice (n= 10) and CTLA-4+/− mice (n= 6) 10 days after surgery, d. and 28 days after surgery
86−/− mice (n= 8) and CTLA-4+/− mice (n= 11) and in e. both 10 and 28 days after surgery
***p b 0.001.(Fig. 3e). These results suggest an important role for the CD27-CD70 T
cell co-stimulation pathway in angiogenesis.
3.6. Decreased arteriogenesis in adductor muscles of CD70−/− mice
Arteriogenesis was determined by counting the number of collateral
arterioles and measuring the diameter of collateral arterioles of smooth
muscle cell (aSMActin) stained adductor muscles of mice sacrificed 10
and 28 days after surgery (typical example of aSMActin staining is
shown in Fig. 4a) and is shown as a ratio of treated compared to un-
treated adductor muscle.
Total number of collateral arterioles in the left paw after arterial liga-
tion was significantly lower in CD70−/− mice 10 days (p = 0.02) and
28 days (p = 0.03) after arterial ligation compared to control mice
(Fig. 4b and c), indicating decreased pre-existing collaterals in CD70−/−
mice. No differences in number of collateral arterioles were observed
in CD80/86−/−, CD70/80/86−/− and CTLA-4+/−mice compared to con-
trol mice 10 and 28 days after surgery.
Collateral arterioles diameter L/R ratio was significantly increased
10 days after surgery in CD70−/− mice (p= 0.01) compared to control
mice and a trend towards an increased diameter of collateral arterioles
was observed in CD70/80/86−/− mice (p= 0.08) compared to control
mice. No differences were observed in CD80/86−/− and CTLA-4+/− ad-
ductormuscles compared to control mice (Fig. 4d). The collateral arteri-
oleswere quantified for small (b20 μm2) and large (N20 μm2) collaterals
10 days after surgery to show an increase in large arterioles. No differ-
ences were found in the number of small collaterals (Fig. S4a). We
showed more large collaterals (N20 μm2) in CD70−/− mice (p= 0.04)
compared to control mice (Fig. S4b).
Collateral arteriole diameterwas significantly increased in CTLA-4+/−
mice (p = 0.009), sacrificed 28 days after surgery (Fig. 4e). No dif-
ferences were found in CD70−/−, CD80/86−/− and CD70/80/86−/−genta) immunofluorescent double staining in soleus muscles is shown with DAPI (blue).
as used for quantification (20× magnification) c. Quantification as L/R (left ischemic/right
rol mice (n = 9), CD80/86−/− mice (n = 10), CD70−/− mice (n = 11), CD70/80/86−/−
of control mice (n= 11), CD80/86−/− mice (n= 11), CD70−/− mice (n= 7), CD70/80/
. Data are calculated as the ratio of L/R and presented as mean SEM; *p b 0.05; **p b 0.01,
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large collateral arterioles were higher in CTLA-4+/− mice compared
to control mice (Fig. S4c and S4d). CD70−/− mice did not show an
increased number of small or large collateral arterioles 28 days after
surgery. Comparison of collateral arterioles diameter L/R ratio after 10
and 28 days showed significantly increased diameter of collateral arte-
rioles in time in control, CD80/86−/− and CTLA4+/− adductor muscles
and a decrease in collateral arterioles diameter in CD70−/− adductor
muscles. CD70/80/86−/−mice showed no difference in collateral arteri-
oles diameter L/R ratio in time (Fig. 4f). In conclusion, these results sug-
gest an important role for the CD27-CD70 T cell co-stimulation pathway
in arteriogenesis.Fig. 4. Arteriogenesis in adductor muscles. a. Representative image ofαSMActin staining in add
left paw 10 days after surgery in control (n= 9), CD80/86−/− (n= 10), CD70−/− (n= 11), CD
shown in the left paw 28 days after surgery in control (n = 11), CD80/86−/− (n = 11), CD7
αSMActin positive collateral arterioles, presented as L/R (left ischemic/right non-ischemic) ra
after surgery. Data are presented as mean SEM; *p b 0.05; **p b 0.01, ***p b 0.001.4. Discussion
The current study demonstrates an important role for the CD27-
CD70 T cell co-stimulation pathway in angiogenesis, arteriogenesis
and vasculogenesis. The CD28-CD80/86 T cell co-stimulation pathway
showed to be of great importance in T cell activation in lymphoid organs
and bonemarrow. Blood flow recovery after induction of HLI showed to
be significantly impaired in mice lacking CD70, while in CD80/86−/−
mice andCTLA4+/− mice no effect was observed, which indicates
a particular important role of the CD27-CD70 T cell co-stimulation
pathway in neovascularization. CD70 deficiency resulted in impaired
vasculogenesis, as the number of pre-existing collaterals was reduceductor muscle tissue (20×magnification). b. Number of collateral arterioles is shown in the
70/80/86−/− (n= 10) and in CTLA-4+/−mice (n= 6). c. Number of collateral arterioles is
0−/− (n = 7), CD70/80/86−/− (n = 8) and in CTLA-4+/− mice (n = 11). d. Diameter of
tio, is shown 10 days after surgery, e. 28 days after surgery and f. in both 10 and 28 days
189K.H. Simons et al. / International Journal of Cardiology 260 (2018) 184–190in the pia mater. This impaired vasculogenesis also affected the skeletal
muscle, as the number of pre-existing collaterals was also decreased in
the adductor muscle of CD70−/−mice, which led to a severely impaired
blood flow recovery after ischemia. Furthermore, mice lacking CD70 or
CD80/86 showed reduced angiogenesis in soleus muscles 10 days after
ligation. In conclusion, the CD27-CD70 T cell co-stimulation pathway
showed to be most important in pre-existing collateral formation and
post-ischemic blood flow recovery, by arteriogenesis and angiogenesis.
This conclusion was substantiated by the fact that the CD28-CD80/
86 T cell co-stimulation pathway did not show an effect on either
vasculogenesis, arteriogenesis or blood flow recovery. CD80/86−/−
mice demonstrated a similar number of pre-existing collaterals as
the control mice and both CD80/86−/− mice and CTLA4+/− mice
showed the same pattern of blood flow recovery as the control mice
after induction of HLI. Since we observed no effect of the CD28-CD80/
86 T cell co-stimulation pathway on blood flow recovery, the effect of
CD70/80/86−/− mice on blood flow recovery is most likely explained
by the lack of CD70 co-stimulation.
Previous studies showed that the CD28-CD80/86 T cell co-
stimulation pathway and CD28-CTLA4 T cell inhibitory pathway regu-
late the development of native atherosclerosis [23,24] via reduced T
cell activation and proliferation and thus decreased presence of IFNγ
producing T cells, and regulatory T cells. Inhibition of the CD28-CD80/
86 T cell co-stimulation pathway with abatacept showed beneficial ef-
fects on interventional accelerated atherosclerosis, most likely caused
by decreased CD4+ T cell activation [25]. These studies are in contrast
with our study since we here describe an important role of the CD27-
CD70 co-stimulation pathway and not the CD28-CD80/86 T cell co-
stimulation pathway in neovascularization. However, these studies
were performed in an atherosclerosis model, and not in a HLI model.
Furthermore, other T cell co-stimulatory and inhibitory pathways such
as PD1, OX40, CD40 and 4-1BB also showed to be involved in vascular
diseases [32], although interesting, that is beyond the scope of this
study. The CD27-CD70 T cell co-stimulation pathway showed beneficial
effect on atherosclerosis, due to monocytes that were susceptible to ap-
optosis and in that way prevented atherosclerotic plaque formation
[31]. This is line with our study where we show a detrimental effect of
CD70 deficientmice in neovascularization, suggesting a beneficial effect
of CD70 in neovascularization in mice without CD70 deficiency. A par-
ticular important role of the CD27-CD70 and not the CD28-CD80/86 T
cell co-stimulation pathway in our study could be due to the constitu-
tively expression of CD27 and CD28 on T cells [18,33,34], while CD80,
CD86, and CD70 are transiently up regulated upon activation on differ-
ent APCs that contribute to neovascularization e.g. VSMCs, endothelial
cells, macrophages or dendritic cells. We here showed that CD80/
CD86 did not influence the VSMC functionality and only lack of CD70
resulted in an impaired function of VSMC which can contribute to im-
paired pre-existing collateral formation and arteriogenesis via decreased
attraction of inflammatory cells via VSMCs. Although CD27 and CD28 are
constitutively expressed on resting T cells, CD27 and CD28 expression
is lost after differentiation into effector T cells. Transient co-stimulation
expression on these cell types might lead to differential functions of
co-stimulation. Furthermore, it is shown previously that CD28 promotes
T cell proliferation and activation, while CD27 stimulated cell survival.
We suggest that the differential functions and expression of individual
co-stimulation and inhibitory pathwaysmight lead to differential effects
on neovascularization.
This study shows that a combination of all aspects of neovasculariza-
tion is essential for post-ischemic bloodflow recovery. Neovessel forma-
tion may be either de novo via vasculogenesis or under pathological
conditions via angiogenesis [35,36]. Together with arteriogenesis, the
body can naturally restore a hampered blood flow. In this study, im-
paired angiogenesis, arteriogenesis and vasculogenesis showed all to
be involved in the impaired blood flow recovery in mice lacking CD70,
and only an increase in diameter of collateral arterioles was not suffi-
cient to restore bloodflow in the paw after ligation of the femoral artery.Weexpected a decrease in pre-existing collaterals sincewe also showed
an impairment in the ability to activate T cells in CD70−/− and CD70/80/
86−/− VSMCs in vitro and VSMCs contribute to the development of the
pre-existing collaterals via VEGF regulation [37].
However, with an increase in diameter of collateral arterioles, an in-
crease in post-ischemic blood flow recovery could be expected.We here
show a decreased post-ischemic blood flow recovery in CD70−/− mice
with an increased diameter of collateral arterioles in adductor muscles,
which is counterintuitive. This could be explained by the reduced num-
ber of collateral arterioles observed in the adductor muscles of the
ligatedpaws in CD70−/−micewhich can lead to a higher blood pressure
in the present collateral arterioles after induction of HLI. This can lead to
shear stress and attraction of monocytes and macrophages, which can
explain the increased diameter of collateral arterioles in CD70−/−
mice 10 days after surgery. The impaired angiogenesis and reduced
number of pre-existing collaterals in mice lacking CD70 contributed
to a reduced blood flow recovery and only an increased diameter of
collateral arterioles in the CD70 deficient mice could not restore blood
flow. This indicates that after arterial obstruction, blood flow can only
be restored when all components of neovascularization including
vasculogenesis, angiogenesis and arteriogenesis, are fully functional.
We here described a different function of co-stimulatory pathways
in lymphoid organs, in the systemic circulation and in peripheral tissues.
With an important role of the CD28-CD80/86 co-stimulation pathway
for T cell activation in lymphoid organs and bone marrow, and the
CD27-CD70 co-stimulation pathway in peripheral tissues after ischemia
is induced. Previous studies also showed opposed systemic and periph-
eral effects of monocytes. An enhanced systemic activation of Ly6Chi
monocytes, but a reduced infiltration of Ly6Chi monocytes into periph-
eral muscle tissue was shown after HLI in RP105 (a TLR4 homologue)
deficient mice, which resulted in reduced blood flow recovery in
RP105 deficient mice [38]. Another study showed improved post-
ischemic blood flow recovery after intravenous infusion of T cell pre-
stimulated monocytes. Monocytes were circulating in the blood, but
not present in the vessel wall, suggesting a more systemic effect of
T cell pre-stimulated monocytes [39]. Furthermore, after HLI, CD4+
T cells were specifically accumulated in adductor muscles regulated
via the CCR7-CCL19/CCL21 axis [40]. Which can explain our opposed
systemic and peripheral effects of co-stimulation.
In conclusion, we here show an important role for T cell activation
via co-stimulation in angiogenesis, arteriogenesis and vasculogenesis,
were the CD27-CD70 T cell co-stimulation pathway appears to be the
most important T cell co-stimulation factor in pre-existing collateral for-
mation and post-ischemic blood flow recovery, by arteriogenesis and
angiogenesis.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2018.02.015.
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